scholarly journals High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives

2019 ◽  
Vol 20 (24) ◽  
pp. 6258 ◽  
Author(s):  
Biscetti ◽  
Rando ◽  
Nardella ◽  
Cecchini ◽  
Pecorini ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Central Nervous System ◽  
Nervous System ◽  
Nuclear Protein ◽  
State Of The Art ◽  
High Mobility ◽  
High Mobility Group ◽  
Future Perspectives ◽  
Vascular Bed

Diabetes mellitus (DM) is an endemic disease, with growing health and social costs. The complications of diabetes can affect potentially all parts of the human body, from the heart to the kidneys, peripheral and central nervous system, and the vascular bed. Although many mechanisms have been studied, not all players responsible for these complications have been defined yet. High Mobility Group Box-1 (HMGB1) is a non-histone nuclear protein that has been implicated in many pathological processes, from sepsis to ischemia. The purpose of this review is to take stock of all the most recent data available on the role of HMGB1 in the complications of DM.

scholarly journals Epochal neuroinflammatory role of high mobility group box 1 in central nervous system diseases

2017 ◽  
Vol 4 (2) ◽  
pp. 185-218 ◽  
Author(s):  
Seidu A. Richard ◽  
◽  
Wu Min ◽  
Zhaoliang Su ◽  
Hua-Xi Xu ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
High Mobility ◽  
High Mobility Group ◽  
Nervous System Diseases ◽  
Central Nervous System Diseases

High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics

2019 ◽  
Vol 20 (14) ◽  
pp. 1474-1485 ◽  
Author(s):  
Eyaldeva C. Vijayakumar ◽  
Lokesh Kumar Bhatt ◽  
Kedar S. Prabhavalkar
Keyword(s):  
Myocardial Infarction ◽  
Vagus Nerve Stimulation ◽  
Nuclear Protein ◽  
Therapeutic Potential ◽  
High Mobility ◽  
Dna Binding Protein ◽  
High Mobility Group ◽  
Eukaryotic Cells ◽  
Hmgb1 Protein

High mobility group box-1 (HMGB1) mainly belongs to the non-histone DNA-binding protein. It has been studied as a nuclear protein that is present in eukaryotic cells. From the HMG family, HMGB1 protein has been focused particularly for its pivotal role in several pathologies. HMGB-1 is considered as an essential facilitator in diseases such as sepsis, collagen disease, atherosclerosis, cancers, arthritis, acute lung injury, epilepsy, myocardial infarction, and local and systemic inflammation. Modulation of HMGB1 levels in the human body provides a way in the management of these diseases. Various strategies, such as HMGB1-receptor antagonists, inhibitors of its signalling pathway, antibodies, RNA inhibitors, vagus nerve stimulation etc. have been used to inhibit expression, release or activity of HMGB1. This review encompasses the role of HMGB1 in various pathologies and discusses its therapeutic potential in these pathologies.

scholarly journals Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies

Pharmaceutics ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 542
Author(s):  
Maria Inês Teixeira ◽  
Maria Helena Amaral ◽  
Paulo C. Costa ◽  
Carla M. Lopes ◽  
Dimitrios A. Lamprou
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
State Of The Art ◽  
Physicochemical Characteristics ◽  
Future Perspectives ◽  
Invaluable Tool ◽  
Recent Developments ◽  
The Central Nervous System ◽  
Cns Delivery ◽  
Reproducible Manner

Neurodegenerative diseases (NDs) bear a lot of weight in public health. By studying the properties of the blood-brain barrier (BBB) and its fundamental interactions with the central nervous system (CNS), it is possible to improve the understanding of the pathological mechanisms behind these disorders and create new and better strategies to improve bioavailability and therapeutic efficiency, such as nanocarriers. Microfluidics is an intersectional field with many applications. Microfluidic systems can be an invaluable tool to accurately simulate the BBB microenvironment, as well as develop, in a reproducible manner, drug delivery systems with well-defined physicochemical characteristics. This review provides an overview of the most recent advances on microfluidic devices for CNS-targeted studies. Firstly, the importance of the BBB will be addressed, and different experimental BBB models will be briefly discussed. Subsequently, microfluidic-integrated BBB models (BBB/brain-on-a-chip) are introduced and the state of the art reviewed, with special emphasis on their use to study NDs. Additionally, the microfluidic preparation of nanocarriers and other compounds for CNS delivery has been covered. The last section focuses on current challenges and future perspectives of microfluidic experimentation.

Role of the 5-HT7 Receptor in the Central Nervous System: from Current Status to Future Perspectives

2011 ◽  
Vol 43 (3) ◽  
pp. 228-253 ◽  
Author(s):  
Anne Matthys ◽  
Guy Haegeman ◽  
Kathleen Van Craenenbroeck ◽  
Peter Vanhoenacker
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Current Status ◽  
Future Perspectives ◽  
The Central Nervous System

Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects

Cytokine ◽  
2003 ◽  
Vol 24 (6) ◽  
pp. 254-265 ◽  
Author(s):  
Kevin A. O'Connor ◽  
Michael K. Hansen ◽  
C. Rachal Pugh ◽  
Molly M. Deak ◽  
Joseph C. Biedenkapp ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Proinflammatory Cytokine ◽  
High Mobility ◽  
High Mobility Group

scholarly journals High Mobility Group Box 1 Protein Induction byMycobacterium BovisBCG

2007 ◽  
Vol 2007 ◽  
pp. 1-8 ◽  
Author(s):  
Péter Hofner ◽  
György Seprényi ◽  
András Miczák ◽  
Krisztina Buzás ◽  
Zsófia Gyulai ◽  
...  
Keyword(s):  
Mycobacterium Bovis ◽  
In Vitro Model ◽  
Nuclear Protein ◽  
High Mobility ◽  
High Mobility Group ◽  
Pathophysiological Role ◽  
Vitro Model

High mobility group box 1 protein (HMGB1), a nuclear protein, is a critical cytokine that mediates the response to infection, injury, and inflammation. The aim of our study was to elaborate a reliable in vitro model to investigate whetherMycobacterium bovisBCG is able to induce HMGB1 secretion from the monocytic U-937 cells. Western blot technique was applied for the detection of HMGB1 from supernatants of cells, following induction withMycobacterium bovisBCG. Densitometric analysis revealed higher concentrations of HMGB1 in cell supernatants stimulated with BCG than in the supernatants of the control, nonstimulated cells. Further quantitation of the secreted HMGB1 was performed by ELISA. The BCG strain resulted in a higher amount of secreted HMGB1 (450±44 ng/mL) than that of LPS (84±12 ng/mL) orStaphylococcus aureus(150±14 ng/mL). BCG and Phorbol−12-myristate−13acetate (PMA), added together, resulted in the highest HMGB1 secretion (645±125 ng/mL). The translocation of the HMGB1 towards the cytoplasm following infection of cells with BCG was demonstrated by immunofluorescence examinations. Conclusion: Our pilot experiments draw attention to the HMGB1 inducing ability ofMycobacterium bovis. Assesment of the pathophysiological role of this late cytokine in mycobacterial infections demands further in vitro and in vivo examinations.

scholarly journals Analysis of the Role of Neurospecific Proteins in the Diagnosis of Cognitive Dysfunction in Patients with Type 1 Diabetes Mellitus

2014 ◽  
Vol 17 (2) ◽  
pp. 83-90 ◽  
Author(s):  
Yulia Gennad'evna Samoylova ◽  
Maria Vladimirovna Novoselova ◽  
Natalya Grigor'evna Zhukova ◽  
Olga Sergeevna Tonkikh
Keyword(s):  
Diabetes Mellitus ◽  
Central Nervous System ◽  
Nervous System ◽  
Cognitive Dysfunction ◽  
Structural Changes ◽  
Neurospecific Proteins ◽  
The Central Nervous System ◽  
The Brain

Background. Impairment of the central nervous system manifested as cognitive dysfunction caused by metabolic or structural changes is a severe progressive vascular complication of type 1 diabetes mellitus (T1DM). Significant difficulties in the diagnosis of cognitive dysfunction are associated with subjective diagnostic techniques. Objective. To identify the role of neurospecific markers in the diagnosis of cognitive dysfunction in patients with T1DM. Materials and Methods. A total of 58 patients with T1DM aged 16?30 years were included in this study. The control group included 29 healthy young adults matched by gender and age. The survey included clinical and laboratory examinations, psychological testing and magnetic resonance imaging (MRI) of the brain. The Montreal Cognitive Assessment (MoCA) was used to screen for cognitive impairment. The levels of neurospecific proteins (S100, glial fibrillary acidic protein and myelin basic protein) were determined to identify early markers of cognitive impairment. MRI of the brain was performed using a Siemens Magnetom 1.0 T system to assess structural changes in the central nervous system. Results. The study revealed increased levels of all neurospecific proteins, which correlated with parameters of hyperglycaemia and cognitive deficit (MoCA scores of

Sign in / Sign up

Export Citation Format

Share Document